Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02048007 · ClinicalTrials.gov registry record · Phase 4
Mortality Reduction After Oral Azithromycin: Morbidity Study
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 72,000
- Enrollment target
NCT02048007 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 72,000 participants.
The verdict
NCT02048007, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 72,000 participants
- Enrollment target
Study Summary
The long-term goal of this study is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood morbidity and increasing growth, and for the potential selection of antibiotic resistance. The investigators propose a set of 3 cluster-randomized trials in Malawi, Niger, and Tanzania comparing communities randomized to oral azithromycin with those randomized to placebo. To assess the generalizability of the intervention, investigators will monitor for antibiotic resistance, which could potentially limit adoption of mass antibiotic treatments. The investigators will also assess several measures of infectious diseases. The investigators hypothesize that mass azithromycin treatments will reduce childhood morbidity and will be accompanied by an acceptable level of antibiotic resistance.
Interventions
- DRUG Placebo
- DRUG Azithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72,000 participants |
| Start Date | 2014-11 |
| Est. Completion | 2020-08-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02048007
The ClinicalTrials.gov registry entry for NCT02048007 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 72,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02048007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02048007 about?
NCT02048007 is a clinical study titled "Mortality Reduction After Oral Azithromycin: Morbidity Study". The long-term goal of this study is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood morbidity and increasing growth, and for the potential selection of antibiotic resistance. The investigators propose a set of 3 cluster-randomized trials in...
What is the current status of trial NCT02048007?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 72,000 participants. The study started on 2014-11. Estimated completion is 2020-08-27.
What interventions are being tested in trial NCT02048007?
The interventions under investigation include: Placebo (DRUG), Azithromycin (DRUG).
Who is sponsoring clinical trial NCT02048007?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.